Annual Meeting of the American Radium Society (ARS)

The purpose of our study is to report our institutional outcomes in treatment of brainstem metastases with gamma knife stereotactic radiosurgery for comparison.

Temporal lobe radionecrosis is a potential complication of high-dose radiation therapy for skull base tumors. The risk of radionecrosis increases with absolute doses greater than 60 Gy, but little data are available regarding potential partial volume effects when higher-dose conventionally fractionated radiotherapy is employed.

Previous data from our institution suggest that imaging evidence of extracapsular extension, identified on pretreatment CT scans, independently predicts for worse distant control and survival for oropharyngeal squamous cell cancer (OPC) patients undergoing radiation therapy. In this present study, we sought to validate these findings in non-OPC head and neck squamous cell cancers.

Our objective was to analyze the incidence of second primary cancer limited to the head and neck in a population with primary squamous cell carcinoma of the head and neck and its temporal trends in the human papillomavirus (HPV) era.

The purpose of this study is to report the long-term progression-free survival (PFS), overall survival (OS), and late-toxicity outcomes in pediatric patients with craniopharyngioma who have been treated with IMRT.

Low-grade gliomas (LGGs) are slow-growing, primary brain tumors that frequently recur after primary surgical treatment. Recent work has established the activation of the PI3K/mTOR pathway in most LGGs, raising the possibility that mTOR inhibitors, such as everolimus (RAD001), may benefit patients with LGG. Early imaging markers of treatment response and disease progression are needed to assess patients undergoing investigational therapy.

The purpose of our study is to evaluate the outcomes of patients treated with SBRT in the postoperative setting.

Single-fraction palliative radiotherapy for bone metastasis appears to be much more available for cancer patients receiving end-of-life care within the United Veterans Healthcare Administration when compared with the general US health care system.

The goal of this study is to compare survival, local control, and toxicity outcomes for non–small-cell lung cancer patients treated with SBRT for centrally versus peripherally located tumors.

Neoadjuvant chemoradiation is a standard treatment of locally advanced esophageal cancer. Preventive strategies to minimize postoperative morbidity will be important to help improve the clinical outcomes of patients. We investigated the factors associated with an increased incidence of anastomotic leaks among patients treated with neoadjuvant chemoradiation.

In this retrospective study, we sought to investigate the dose prescription pattern use in the US for patients receiving SBRT.

We evaluated the correlation between patient survival and reduction in gross tumor volume (GTV) using weekly cone-beam computed tomography (CBCT) to assess whether this could be prognostic of survival. We hypothesized that a greater percent decline in primary lung tumor volume during the course of treatment would correlate to improved patient survival.

The goal of this study was to optimize combination therapy with PARP1 inhibition and radiation for clinical assessment by establishing the most effective drug/radiation treatment schedule, determining the degree of PARP1-mediated radiosensitization across a range of drug doses, and identifying early biomarkers predictive of long-term treatment efficacy in preclinical BCa models.

There is conflicting evidence regarding the benefit of postmastectomy radiation therapy (PMRT) for pathologic stage T3N0M0 breast cancers. We performed a Surveillance, Epidemiology, and End Results (SEER) analysis to investigate the benefit of PMRT in these patients.

Purpose: Rhabdomyosarcoma of the perineal and perianal region (PRMS) has poor outcomes. We analyzed prognostic factors and patterns of failure, with an emphasis on radiotherapy for locoregional control.

To compare rates of pathologic response, downstaging, local control, and treatment-related toxicity in patients treated in a prospective phase II trial of preoperative short-course radiotherapy and sequential FOLFOX (folinic acid, fluorouracil, oxaliplatin) chemotherapy with patients treated at our institution with preoperative long-course chemoradiotherapy and adjuvant chemotherapy.

Although adverse sequelae of chemoradiation (CRT) for head and neck cancer (HNC) have been extensively detailed in recent years, the effects of CRT on voice and speech quality remain poorly characterized. We investigated changes in patient-reported voice and speech quality (VSQ) after CRT in two prospective studies of organ-sparing CRT for locally advanced oropharyngeal cancer (OPC).

To characterize the utilization of postprostatectomy radiation for patients with prostate cancer (CaP) at a National Cancer Institute (NCI)-designated Comprehensive Cancer Center over the past decade, given the introduction of robotic prostatectomy and the publication of multiple phase III trials showing a benefit for adjuvant postprostatectomy radiation.

Permanent prostate brachytherapy (PPB) is a well-established treatment for localized prostate cancer. The future of PPB relies upon the quality training of future residents; however, current training requirements are frequently inadequate. Our objective was to design and implement a unique training program that utilized a phantom-based simulator to teach the process of quality assurance (QA) and improve PPB education.

This prospective study expands upon prior studies to further evaluate SBRT efficacy and QOL for a large patient population that includes low-, intermediate-, and high-risk prostate cancer patients.

To investigate outcomes in intermediate-risk prostate cancer patients receiving dose-escalated external beam radiation therapy (RT) with or without short-course androgen deprivation therapy (ADT).

To determine if there is an influence of sociodemographic factors on biochemical control (bNED) and overall survival (OS) in prostate cancer (CaP).

This study estimates RT doses received by organs of interest during protocol treatment to determine whether the findings might explain these observations.

We hypothesized that the promising outcomes with partial-bladder treatment might be due to the effects of hypofractionation. We thus aimed to analyze the clinical impact of hypofractionation on local control and to characterize the radiation response of a bladder cancer cell line with regard to clonogenic survival.

One clinical observation is that a decrease in tumor enhancement on CT scans after cytotoxic therapy is generally regarded as a good response. We hypothesized that measuring this phenomenon would correlate with local control of human pancreatic adenocarcinoma (PDAC).

Chemoradiation for biliary tract cancers (BTCs) has been associated with substantial toxicities due to the large, irregular target volumes surrounded by critical normal tissues. The purpose of this study was to evaluate patient tolerability and acute toxicity of chemoradiation with intensity-modulated radiation therapy (IMRT) for BTCs.

In this study, we investigate the role of ALDH expression in predicting survival and patterns of disease recurrence in pancreatic adenocarcinoma patients treated with chemoradiation following pancreatectomy.

For patients with pancreatic cancer, we compared direct care costs, patient retention rates, and survival outcomes for patients treated in our institution’s pancreatic multidisciplinary clinics (MDCs) with those evaluated within the institution but outside the MDC.

Evaluation of liver function following high-dose liver stereotactic body radiation therapy (SBRT) in the treatment of metastatic and primary malignancies of the liver utilizing the Child-Pugh score classification system.

Hypofractionated whole-breast irradiation (HF-WBI) following breast-conserving surgery has produced excellent outcomes, but utilization remains limited. We evaluated the impact of a clinical pathway on adoption of HF-WBI in a large integrated radiation oncology network.